Literature DB >> 30810402

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review.

Zsófia Mészner1, Jacek Wysocki2, Darko Richter3, Dace Zavadska4, Inga Ivaskeviciene5,6, Vytautas Usonis5, Marko Pokorn7, Atanas Mangarov8, Ligita Jancoriene6,9, Sorin C Man10, Zuzana Kristufkova11, Milos Jesenak12, Goran Tešović13, Justyna Pluta14, Lara J Wolfson15.   

Abstract

INTRODUCTION: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in both individual burden and societal costs. Despite these benefits, there is no standardization of varicella immunization policies in Europe, including countries in Central and Eastern Europe (CEE). AREAS COVERED: This systematic literature review identified publications on the epidemiology of varicella, its associated health and economic burden, and vaccination strategies within the CEE region, defined as Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, and Slovenia. Twenty-six studies were identified from a search of PubMed, Embase®, and MEDLINE® biomedical literature databases, supplemented by gray literature and country-specific/global websites. EXPERT COMMENTARY: Limited information exists in published studies on the burden of varicella in CEE. The wide variability in incidence rates between countries is likely explained by a lack of consistency in reporting systems. Funded universal varicella vaccination (UVV) in CEE is currently available only in Latvia as a one-dose schedule, but Hungary together with Latvia are introducing a two-dose strategy in 2019. For countries that do not provide UVV, introduction of vaccination is predicted to provide substantial reductions in cases and rates of associated complications, with important economic benefits.

Keywords:  Burden of illness; Central and Eastern Europe; systematic literature review; vaccination; varicella

Mesh:

Substances:

Year:  2019        PMID: 30810402     DOI: 10.1080/14760584.2019.1573145

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  5 in total

1.  Acceptance of varicella vaccination.

Authors:  Andrea Horváth
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

2.  Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.

Authors:  Erin M Paradis; Oleg Tikhonov; Xin Cao; Susanna M Kharit; Aleksandr Fokin; Heather L Platt; Natalie Banniettis
Journal:  Hum Vaccin Immunother       Date:  2021-09-02       Impact factor: 4.526

3.  Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.

Authors:  Erin M Paradis; Oleg Tikhonov; Xin Cao; Susanna M Kharit; Aleksandr Fokin; Heather L Platt; Frederick Wittke; Veronika Jotterand
Journal:  Hum Vaccin Immunother       Date:  2021-10-26       Impact factor: 3.452

4.  The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.

Authors:  Colleen Burgess; Stephanie Kujawski; Ajda Lapornik; Goran Bencina; Manjiri Pawaskar
Journal:  J Health Econ Outcomes Res       Date:  2022-09-20

5.  Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.

Authors:  Giacomo Casabona; Md Ahsan Habib; Michael Povey; Marianne A Riise Bergsaker; Carl-Erik Flodmark; Ketil Arne Espnes; Camilla Tøndel; Sven-Arne Silfverdal
Journal:  Acta Paediatr       Date:  2021-10-28       Impact factor: 4.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.